wx390
PIK3CA Mutation-Related Tumors
Shanghai Jiatan Pharmatech Co., LtdPhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the PIK3CA Mutation-Related Tumors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pyruvate Pamela Munster | Phase 1 | CC |
Carboplatin Pamela Munster | Phase 1 | CC |
Alpelisib Pamela Munster | Phase 1 | CC |
Same molecule, other indications
wx390 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →